Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 85

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 85
---
 with the roll-over shares from the Company’s 2011 Equity Incentive Plan, 3.4 million shares of common stock remain available for future grant under the 2018 Plan.In March 2024, the Company initiated the 2024 Employment Commencement Incentive Plan (the “2024 Plan”). The 2024 Plan, which authorized 0.6 million shares of common stock to be issued, allows for the grant of stock options, SARs, RSAs, RSUs, performance shares and performance units. In June 2024, there was an addition of 0.5 million shares to the 2024 Plan. As of December 31, 2024, 1.0 million shares of common stock remain available for future grant under the 2024 Plan. Stock OptionsIn general, stock options have a ten-year term and vest over a four-year period, with one-fourth of the underlying shares vesting on the first anniversary of the grant and 1/48th of the underlying shares vesting monthly thereafter, such that the underlying shares will be fully vested on the fourth anniversary of the grant, subject to the terms of the applicable plan under which they were granted.The fair values of stock options granted during the periods presented are measured on the date of grant using the Black-Scholes-Merton option-pricing model, with the following assumptions:  

        For the Year Ended December 31,

        2024
         
        2023
         
        2022

        Risk-free interest rate (1)
         
        3.5 - 4.4%
         
        3.5 - 4.9%
         
        1.6 - 4.2%

        Expected dividend yield (2)
         
        —
         
        —
         
        —

        Expected term (3)
         
        5.81 years
         
        5.23 years
         
        5.09 years

        Expected volatility (4)
         
        40.8 - 53.5%
         
        46.8 - 63.2%
         
        52.4 - 72.9%
       
       (1)The risk-free interest rate is estimated using an average of Treasury bill interest rates over a historical period commensurate with the expected term of the option that correlates to the prevailing interest rates at the time